Cancer-associated thrombosis – treatment and prevention with direct oral factor Xa inhibitors

Czech version

Authors: K. Grilusová ¹; T. Bolek ¹; I. Škorňová ²; J. Staško ²; M. Samoš ¹; M. Mokáň ¹
Authors‘ workplace: I. Interná klinika JLF UK a UN Martin, Slovenská republika ¹; Klinika hematológie a transfuziológie, Národné centrum trombózy a hemostázy SR, JFK UK Martin, Slovenská republika ²
Published in: Klin Onkol 2021; 34(4): 283-290
Category: Review
doi: https://doi.org/10.48095/ccko2021283

Overview

Background: Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in patients with cancer. Moreover, management of VTE is frequently connected with complications, namely risk of recurrent VTE and bleeding. Low molecular weight heparins (LMWH) therapy administrated for 3–6 months is currently considered a standard for the treatment of cancer-associated VTE (CA-VTE). Direct oral factor Xa inhibitors (FXaI) apixaban, edoxaban and rivaroxaban have emerged as a new possibility for long-term antithrombotic therapy for VTE. These agents expose several advantages in individuals with cancer, and might overcome several disadvantages connected with LMWH therapy. Purpose: First clinical studies with oral FXaI for the treatment of CA-VTE with very promising results were recently published. The article summarizes current data regarding the use of oral FXaI in the treatment of CA-VTE.

Keywords:

cancer-associated venous thromboembolic disease – Pulmonary embolism – Deep vein thrombosis – direct oral factor Xa inhibitors

Sources

1. Pabinger I, van Es N, Heinze G, Posch F, Riedl J et al. A clinical prediction model for cancer associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5 (7): e289–e298. doi: 10.1016/S2352-3026 (18) 30063-2.

2. Lyman GH, Khorana AA, Kuderer NM et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17): 2189–2204. doi: 10.1200/JCO.2013.49.1118.

3. Muldera FI, van Esa N, Kraaijpoela N et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thromb Res 2020; 185: 13–19. doi: 10.1016/j.thromres.2019.11.007.

4. Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (7): 615–624. doi: 10.1056/NEJMoa1711948.

5. Corsini A, Ferri N, Proietti M et al. Edoxaban and the issue of drug-drug interactions: from pharmacology to clinical practice. Drugs 2020; 80 (11): 1065–1083. doi: 10.1007/s40265-020-01328-6.

6. Hirsh J, Ginsberg JS. Edoxaban for the treatment of venous thromboembolism in patients with cancer. N Engl J Med 2018; 378 (7): 673–674. doi: 10.1056/NEJMe1800041.

7. Kvasnicka T, Malikova I, Zenahlikova Z et al. Rivaroxaban – metabolism, pharmacologic properties and drug interactions. Curr Drug Metab 2017; 18 (7): 636–642. doi: 10.2174/1389200218666170518165443.

8. Weitz JI, Lensing AWA, Prins MH et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13): 1211–1222. doi: 10.1056/NEJMoa1700518.

9. Bauersachs R, Khorana AA, Lee AYY et al. Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. Res Pract Thromb Haemost 2020; 4 (4): 532–549. doi: 10.1002/rth2.12327.

10. Young AM, Marshall A, Thirlwall J et al. Comparison of an oral Factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20): 2017–2023. doi: 10.1200/JCO.2018.78.8 034.

11. Khorana AA, Soff GA, Kakkar AK et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380 (8): 720–728. doi: 10.1056/NEJMoa1814630.

12. Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). [online]. Available from: https: //clinicaltrials.gov/ct2/show/NCT02746185.

13. Mantha S, Laube E, Miao Y et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospectivecohort study. J Thromb Thrombolysis 2017; 43 (2): 166–171. doi: 10.1007/s11239-016-1429-1.

14. Direct oral anticoagulants (DOACs) versus lmwh +/- warfarin for VTE in cancer (CANVAS). [online]. Available from: https: //clinicaltrials.gov/ct2/show/NCT02744092.

15. Kubisz P, Stanciakova L, Dobrotova M et al. Apixaban – metabolism, pharmacologic properties and drug interactions. Curr Drug Metab 2017; 18 (7): 609–621. doi: 10.2174/1389200218666170424151551.

16. Weycker D, Li X, Wygant GD et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thromb Haemost 2018; 118 (11): 1951–1961. doi: 10.1055/s-0038-1673689.

17. Levine MN, Gu C, Liebman HA et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10 (5): 807–814. doi: 10.1111/j.1538-7836.2012.04693.x.

18. Agnelli G, Becattini C, Bauersachs R et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the caravaggio study. Thromb Haemost 2018; 118 (9): 1668–1678. doi: 10.1055/s-0038-1668523.

19. Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17): 1599–1607. doi: 10.1056/NEJMoa1915103.

20. Ikeda S, Koga S, Yamagata Y et al. Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer. J Cardiol 2018; 72 (2): 120–127. doi: 10.1016/j.jjcc.2018.03.006.

21. Shimizu A, Sawada K, Shiomi M et al. Direct oral anticoagulants are effective and safe for the treatment of venous thromboembolism associated with gynecological cancers. Int J Gynaecol Obstet 2019; 147 (2): 252–257. doi: 10.1002/ijgo.12944.

22. Takama T, Fukue M, Kanaya K et al. Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria. SAGE Open Med Case Rep 2019; 7: 2050313X19878047. doi: 10.1177/2050313X19878047.

23. Samoš M, Bolek T, Škorňová I et al. Anti-Xa activity-guided edoxaban therapy for cancer-associated venous thromboembolism? Am J Ther 2020; [in press]. doi: 10.1097/MJT.0000000000001202.

24. Toshima H, Hisamatsu A, Kobayashi K et al. Single-drug approach with edoxaban is effective for resolving non-acute cancer-associated venous thrombosis: a single-arm retrospective analysis. Cancers (Basel) 2020; 12 (7): 1711. doi: 10.3390/cancers12071711.

25. Connell NT, Connors JM. Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. J Thromb Thrombolysis 2019; 48 (3): 382–386. doi: 10.1007/s11239-019-01903-z.

26. Lopes DG, Tamayo A, Schipp B et al. Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil. Thromb Res 2020; 196: 4–10. doi: 10.1016/j.thromres.2020.08.014.

27. Pignataro BS, Nishinari K, Cavalcante RN et al. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism in 400 patients with active cancer: a single-center experience. Clin Appl Thromb Hemost 2017; 23 (7): 883–887. doi: 10.1177/1076029616677 800.

28. Renni MJP, Araujo MLC Jr, Trugilho I et al. Rivaroxaban used in the treatment patients with gynecologic cancer and venous thromboembolism: the experience of Instituto Nacional de Câncer-Rio de Janeiro, Brazil. Int J Gynecol Cancer 2017; 27 (5): 1042–1045. doi: 10.1097/IGC.0000000000000972.

29. Nicklaus MD, Ludwig SL, Kettle JK. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. J Oncol Pharm Pract 2018; 24 (3): 185–189. doi: 10.1177/1078155217690922.

30. Choe HK, De Sancho MT, Kim SS et al. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies. Blood Coagul Fibrinolysis 2018; 29 (2): 227–230. doi: 10.1097/MBC.0000000000000704.

31. Lee JH, Oh YM, Lee SD et al. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer. J Korean Med Sci 2019; 34 (21): e160. doi: 10.3346/jkms.2019.34.e160.

32. Recio-Boiles A, Veeravelli S, Vondrak J et al. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol 2019; 11 (10): 866–876. doi: 10.4251/wjgo.v11.i10.866.

33. Kim JH, Seo S, Kim KP et al. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in advanced upper gastrointestinal tract and hepatopancreatobiliary cancer. In Vivo 2020; 34 (2): 829–837. doi: 10.21873/invivo.11845.

34. Simmons B, Wysokinski W, Saadiq RA et al. Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism. Eur J Haematol 2018; doi: 10.1111/ejh.13074.

35. Yhim HY, Choi WI, Kim SH et al. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial. Korean J Intern Med 2019; 34 (5): 1125–1135. doi: 10.3904/kjim.2018.097.

36. Søgaard M, Nielsen PB, Skjøth F et al. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study. Cancer Med 2019; 8 (3): 1044–1053. doi: 10.1002/cam4.1997.

37. Soff GA, Mones J, Wilkins C et al. Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Res Pract Thromb Haemost 2019; 3 (3): 349–356. doi: 10.1002/rth2.12215.

38. Faqah A, Sheikh H, Bakar MA et al. Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre. Thromb J 2020; 18: 8. doi: 10.1186/s12959-020-00221-2.

39. Oh SB, Seol YM, Kim HJ et al. Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer-associated venous thromboembolism: a single-center study. Medicine (Baltimore) 2019; 98 (30): e16514. doi: 10.1097/MD.0000000000016514.

40. Lee JH, Hyun DG, Choi CM et al. A retrospective study on efficacy and safety of rivaroxaban and dalteparin for long-term treatment of venous thromboembolism in patients with lung cancer. Respiration 2019; 98 (3): 203–211. doi: 10.1159/000499895.

41. Shimizu A, Sawada K, Shiomi M et al. Direct oral anticoagulants are effective and safe for the treatment of venous thromboembolism associated with gynecological cancers. Int J Gynaecol Obstet 2019; 147 (2): 252–257. doi: 10.1002/ijgo.12944.

42. Lee JH, Lee JH, Jo KW et al. Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. J Gynecol Oncol 2020; 31 (1): e10. doi: 10.3802/jgo.2020.31. e10.

43. Stepien K, Nowak K, Zalewski J et al. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study. Vascul Pharmacol 2019; 120: 106567. doi: 10.1016/j.vph.2019.106567.

44. García-Fernández-Bravo I, Demelo-Rodríguez P, Ordieres-Ortega L et al. Cancer associated phlegmasia cerulea dolens successfully treated with apixaban. Blood Res 2018; 53 (1): 90–92. doi: 10.5045/br.2018.53.1.90.

45. Koga M, Sugimoto A, Furo M et al. Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report. Eur Heart J Case Rep 2018; 2 (4): yty135. doi: 10.1093/ehjcr/yty135.

46. Wysokinski WE, Houghton DE, Casanegra AI et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol 2019; 94 (11): 1185–1192. doi: 10.1002/ajh.25604.

47. Khorana AA, Noble S, Lee AYY et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (9): 1891–1894. doi: 10.1111/jth.14219.

48. Key NS, Khorana AA, Kuderer NM et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (5): 496–520. doi: 10.1200/JCO.19.01 461.

49. Chao TF, Chen SA, Ruff CT et al. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non--Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019; 40 (19): 1518–1527. doi: 10.1093/eurheartj/ehy807.